Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526834 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
A Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT04526834: Active Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Tessa Therapeutics.
NCT04526834 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 21 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04526834, a Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
Primary Outcome
Incidence of DLTs and occurrence of study related adverse events
Conditions Studied
Interventions
- DRUG CD30.CAR-T
Study Locations (4)
Texas
- Baylor College of Medicine - Houston
- The University of Texas MD Anderson Cancer Centre - Houston
California
- City of Hope - Duarte
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2036-03 |
| Phase | Phase 1 |
What the registry record for NCT04526834 still lists
NCT04526834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD30.CAR-T is the first listed.
NCT04526834 reports a single indexed study location in Texas, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04526834 about?
NCT04526834 is a clinical study titled "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma". This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
What is the current status of trial NCT04526834?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-09-08. Estimated completion is 2036-03.
What conditions does trial NCT04526834 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Extranodal NK/T-cell Lymphoma.
What interventions are being tested in trial NCT04526834?
The interventions under investigation include: CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT04526834?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526834 being conducted?
This trial has 4 study locations across California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04526834's enrollment target sits among peer trials
21 96th of 114 higher than 18 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI